Microglial Nr4a1 and Neuronal C3 in TMJ Inflammation-Induced Hippocampal Synaptic Pruning

Study Background and Research Question

Temporomandibular disorder (TMD) is a prevalent condition impacting orofacial function, with a substantial subset of patients experiencing comorbid depression and anxiety. Although the physical aspects of TMD—such as pain and restricted jaw movement—have been well characterized, the central neurobiological mechanisms that link peripheral inflammation to mood disturbances are incompletely understood. The hippocampus (HPC) is a brain region critically involved in emotional regulation and is known to exhibit synaptic remodeling in depressive states. Recent evidence suggests that neuroimmune interactions, particularly via microglial activation and complement-mediated synaptic pruning, may underlie this link. The reference study (Zhu et al., 2026) addresses the question: How do microglial and neuronal molecular changes in the hippocampus mediate depression-like behaviors in TMJ inflammation?

Key Innovation from the Reference Study

The principal innovation of this research lies in its identification of a sequential molecular mechanism whereby TMJ inflammation triggers microglial Nr4a1 (Nuclear receptor subfamily 4 group A member 1) downregulation, leading to NF-κB pathway activation, increased microglial phagocytic activity, and excessive synaptic pruning in the hippocampus. Concurrently, neuronal upregulation of complement component C3 marks synapses for elimination, together culminating in synaptic loss and depression-like behaviors. The study is the first to directly link TMJ-induced peripheral inflammation to central synaptic remodeling through a defined Nr4a1–C3 axis in vivo.

Methods and Experimental Design Insights

• Disease Model: TMJ inflammation was induced in mice using complete Freund’s adjuvant (CFA) injection, creating a robust model of peripheral inflammatory pain and joint dysfunction.
• Behavioral Analysis: Depression-like behaviors were assessed through established paradigms, including the forced swim test and sucrose preference test, to quantify anhedonia and despair.
• Histology and Immunofluorescence: Hippocampal sections were analyzed for microglial activation (Iba1, CD68), synaptic density, and complement C3 deposition. Colocalization studies mapped the spatial relationship between microglia, neurons, and synaptic terminals.
• Genetic Manipulation: Microglial Nr4a1 was selectively knocked down or overexpressed using viral vectors, allowing for cell-type-specific mechanistic interrogation.
• Pharmacological Modulation: Minocycline was employed to inhibit microglial activation, demonstrating the necessity of microglial involvement in synaptic and behavioral changes.

Notably, activation of the NF-κB signaling pathway downstream of Nr4a1 deficiency was confirmed, aligning with broader research on NF-κB–mediated inflammatory signaling in neuroimmune interactions. These methodological strengths enable precise mapping of molecular and cellular events leading from TMJ inflammation to depressive phenotypes.

Protocol Parameters

• CFA-induced TMJ inflammation: Administer CFA locally to the TMJ region; typically, behavioral and histological analyses are performed 7–14 days post-injection.
• Behavioral testing window: 7–14 days after CFA for optimal detection of mood-related phenotypes.
• Microglial modulation: Minocycline can be administered at 50 mg/kg intraperitoneally daily, starting at inflammation onset to inhibit activation.
• Genetic manipulation timing: Viral-mediated Nr4a1 knockdown or overexpression should precede CFA injection by at least 1 week to ensure sufficient expression changes.
• Immunofluorescence analysis: Use Iba1, CD68, and C3 antibodies; quantification of synaptic terminals (e.g., PSD95) should be performed in hippocampal subfields (CA1, dentate gyrus).

Core Findings and Why They Matter

The study’s central findings are:

• TMJ inflammation induces depression-like behaviors in mice, associated with activation of hippocampal microglia and loss of excitatory synapses.
• Microglial Nr4a1 expression is markedly reduced following TMJ inflammation. Knockdown of Nr4a1 enhances NF-κB pathway activity and microglial phagocytic function, as evidenced by increased CD68 expression.
• Neuronal C3 is upregulated and deposited at synaptic sites, where it colocalizes with microglia, promoting synaptic pruning via complement tagging.
• Overexpression of C3 in the hippocampus is sufficient to drive excessive synaptic loss and depression-like behavior, establishing a causal link.
• Pharmacological or genetic suppression of microglial activation (e.g., via minocycline or Nr4a1 overexpression) normalizes synaptic density and alleviates behavioral deficits.

These results establish a mechanistic bridge between peripheral inflammatory insult and central mood regulation, implicating microglial NF-κB signaling and complement-mediated synaptic pruning as therapeutic targets for TMD-associated neuropsychiatric complications. The demonstration that targeting either microglial activation or neuronal complement signaling mitigates depressive behaviors supports a model where neuroimmune crosstalk is central to inflammation-induced mood disorders (full analysis).

Comparison with Existing Internal Articles

The current study’s focus on NF-κB signaling in microglia and synaptic remodeling aligns with broader research on PKC/NF-κB pathway modulation in inflammatory and neuroimmune contexts. For example, internal discussions of Verbascoside highlight its role as a validated PKC/NF-κB inhibitor capable of modulating inflammatory signaling and osteoclastogenesis. While the referenced paper investigates hippocampal microglia and synaptic pruning in neuropsychiatric models, internal resources such as studies on Verbascoside (SKU B3379) demonstrate robust inhibition of RANKL-induced differentiation and cell signaling pathways in myeloid models. Both lines of evidence underscore the importance of precise PKC/NF-κB pathway targeting in controlling immune-mediated cellular changes, though the tissue and disease contexts differ.

Research on PKC/NF-κB inhibitors, including small molecules like Verbascoside, offers conceptual parallels for the modulation of similar pathways in neuroinflammation and synaptic remodeling. However, direct application in CNS models requires careful adaptation, as highlighted by the specificity of the mechanisms elucidated in the hippocampal microglial context of the present study.

Limitations and Transferability

While the reference study provides compelling evidence for the microglial Nr4a1–C3 axis in TMJ inflammation-induced depression-like behavior, several limitations should be noted:

• Species specificity: All experiments were conducted in mice; translation to human TMD and depression requires further validation.
• Model constraints: The CFA-induced TMJ inflammation model captures key aspects of peripheral inflammatory pain but may not encompass the full spectrum of human TMD pathology.
• Cell-type targeting: Viral vectors provided cell-type specificity in mice, but analogous tools for human intervention are less mature.
• Pathway interaction complexity: The study focuses on NF-κB signaling and complement, but other molecular axes may also contribute to neuroimmune crosstalk in depression.

Despite these constraints, the core mechanistic insights regarding microglial NF-κB activation and complement-driven synaptic pruning offer a robust framework for investigating neuroimmune contributions to mood disorders in other inflammatory contexts.

Research Support Resources

For researchers interested in studying PKC/NF-κB-mediated signaling or in developing cell-based models of neuroimmune interaction, high-purity small-molecule inhibitors provide valuable tools for pathway modulation. Verbascoside (SKU B3379) is a well-characterized PKC/NF-κB inhibitor, widely referenced for its role in modulating inflammatory signaling and osteoclastogenesis research. Its defined IC₅₀ in myeloid models and reliable solubility in DMSO or ethanol facilitate reproducible experimental setup across cell-based assays. While direct extrapolation to CNS models requires careful protocol adaptation, this compound is suitable for mechanistic studies involving PKC/NF-κB pathway inhibition in immune and inflammation-related cellular contexts. For detailed protocol guidance and application notes, consult validated literature and internal resource articles as appropriate.